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Abstract
Background: Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder with hypothalamic
dysfunction, early morbid obesity with hyperphagia, and specific psychiatric phenotypes including cognitive and
behavioural problems, particularly disruptive behaviours and frequent temper outbursts that preclude socialization. A
deficit in oxytocin (OT)-producing neurons of the hypothalamic paraventricular nucleus has been reported in these
patients.
Methods: In a double-blind, randomised, placebo-controlled study, 24 adult patients with PWS received a single
intranasal administration of 24 IU of OT or placebo and were tested 45 min later on social skills. Behaviours were
carefully monitored and scored using an in-house grid as follows: over the two days before drug administration,
on the half-day following administration, and over the subsequent two days. All patients were in a dedicated PWS
centre with more than ten years of experience. Patients are regularly admitted to this controlled environment.
Results: Patients with PWS who received a single intranasal administration of OT displayed significantly increased
trust in others (P = 0.02) and decreased sadness tendencies (P = 0.02) with less disruptive behaviour (P = 0.03) in
the two days following administration than did patients who received placebo. In the half-day following
administration, we observed a trend towards less conflict with others (p = 0.07) in the OT group compared with
the placebo group. Scores in tests assessing social skills were not significantly different between the two groups.
Conclusions: This study needs to be reproduced and adapted. It nevertheless opens new perspectives for patients
with PWS and perhaps other syndromes with behavioural disturbances and obesity.
Trial registration number: ClinicalTrials.gov: NCT01038570
Introduction
Prader-Willi syndrome (PWS) is a rare, complex neurode-
velopment genetic disorder arising from the lack of
expression of paternally inherited imprinted genes on
chromosome 15q11-q13 [1]. The syndrome includes
severe neonatal hypotonia with suckling difficulties,
dysmorphia, early onset of hyperphagia and morbid obe-
sity, endocrine dysfunctions, learning disabilities, and
behavioural, social and psychiatric disturbances, leading to
severe consequences and difficult management issues [2].
Patients with PWS display compulsive and ritualistic
behaviour [3], pronounced emotional lability, and a strik-
ing inability to control emotion, which results in frequent
temper outbursts and precludes normal socialisation [4].
The anger often seems to be an expression of frustration
and the feeling of not being understood, but it may also be
due to an impaired capacity to understand the motivations
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of others in the social milieu [5]. These patients display
poor social adjustment, with poor peer relationships, with-
drawal tendencies, and some features of the autism
spectrum.
Interestingly, a deficit in the oxytocin (OT)-producing
neurons of the paraventricular nucleus in the brain of
these patients was reported [6]. OT was identified as a key
neuropeptide involved in social interactions by enhancing
peer recognition and bonding behaviour in numerous spe-
cies [7]. In humans, nasal OT administration improves
emotion recognition and face processing in healthy and
autistic individuals. OT appears to be the main neurohor-
mone to explain empathy and theory of mind (TOM)
[8-14]. TOM is a concept describing the cognitive attri-
bute that allows us to understand the thinking of others
and to take into account their views [15], while empathy is
part of the interpersonal processes that are crucial for
healthy social and moral development [16]. We therefore
hypothesized that this deficit in the oxytocin (OT)-produ-
cing neurons may be related to OT dysfunction, which
would explain at least in part the inability of these patients
to control emotions and their poor social adjustment,
which in turn might explain their unpredictable disruptive
behaviours and frequent temper outbursts.
Given the possible OT deficit and the overlap between
PWS and autism reported elsewhere [5], it seemed logical
to evaluate the effect of OT administration in these
patients. We hypothesised that OT would improve the
behaviour of patients with PWS by improving their ability
to read social cues, thereby facilitating their socialisation.
Materials and methods
We designed a double-blind randomised, placebo-
controlled pilot study (ClinicalTrials.gov Identifier:
NCT01038570) to be conducted in a dedicated PWS cen-
tre, where patients are regularly admitted for one month
and live in a controlled environment. Patients know they
have no free access to food but no doubt about the time
and the content of meals. For each stay, 16 patients with
PWS are admitted and take part in daily planned occupa-
tional and physical group activities. They also receive
medical care as needed and psychological support. The
24 patients included in this study (16 females, 8 males,
median age 28.5 years [18.7 to 43.6], median BMI 43 kg/
m2 [19.4 to 67.4]) were stratified on gender and IQ (med-
ian IQ = 51[45 to 75]). The diagnosis of PWS was geneti-
cally confirmed using the standard DNA methylation test
and subsequent molecular analyses showed a classic gen-
otype distribution. Nineteen patients had a deletion
(79%), three (12.5%) a UPD, and in two cases (8.5%) the
genetic subtype was unknown. Patients as well as parents
or caregivers gave their written consent prior to entering
the study. Exclusion criteria were an abnormal ECG and
other severe cardiovascular problems. Patients were well
known to the team. Each pair of patients of the same
gender and same IQ range was evaluated the same day.
The two patients of the pair received either OT or
placebo in a double-blind randomisation. Patients were
included in the study over the course of three series of
stays.
Each patient received a single intranasal administration
of either placebo (saline solution) or OT (Syntocinon®/-
Spray, Novartis, Basel, Switzerland) with three puffs per
nostril (24 UI). The dose of 24 UI is the most frequently
reported in the literature. As we did not succeed in obtain-
ing empty flasks of Syntocinon® from Novartis, we used a
different flask and the drug was administered by a nurse
from another department of the hospital. This nurse knew
neither the patients nor the study.
The behaviour of the patients was carefully monitored,
scored daily by the team psychologist, and documented
on the case report form for the two days before drug
administration, on the half-day following administration
(early effects) and over the two days following drug
administration (late effects). Both the staff and the rater
were unaware of treatment status. There are currently no
validated grids that evaluate the specific behavioural fea-
tures of patients with PWS that we particularly wanted to
study, i.e. tendencies towards isolation, sadness, and
depression, self-depreciation, self-mutilation, conflicts
with others, disruptive behaviour, interest in friendship,
interest in love affairs, and trust of others. For this rea-
son, we used an in-house grid developed by the care-
givers and based on the routine observation of these
patients in this dedicated centre for PWS with recognized
expertise [17,18]. The criteria that the staff used to fill in
the grid are explained in Table 1. The patients were well
known to the team but the mean behavior status was re-
evaluated during the first week of admission using the
same grid. The behavioural features of the patients were
scored as unchanged, moderately changed, or severely
changed. For each criterion, a negative score reflected
deterioration in the mean behavior status of the patient
while a positive score reflected an improvement. Eating
behaviour was also scored using three categories: usual,
better than usual or worse, based on the analysis of each
meal. The following were evaluated: amount of food
intake per meal, amount of food requested per meal,
duration of meal, and behaviour before/during/after the
meal. To evaluate the early effect of OT, we analysed
only the first meal after drug administration.
Forty-five minutes after the intranasal administration,
three tests evaluating the understanding of social codes
were administered, which lasted one hour. Conversely to
the behavioural grid, there was no pre-administration
evaluation. The Sally and Ann test assesses one’s ability
to understand simple situations by story-telling and pic-
tures [19]. Cartoons depicting more complex social
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situations designed for the evaluation of autistic children
were also used ("Cartoons”, unpublished test). The
“Reading the Mind in the Eyes” test (RMET) assesses
the ability to read emotions from subtle affective facial
expressions, especially in the eyes. A shortened test with
19 images from the 36-item revised version [20] was
chosen by the team psychologist. In these three tests,
TOM is necessary to understand and analyse the social
situations that are presented. Statistical analysis was per-
formed using the Mann-Whiney test, the Wilcoxon test
or the chi2 test.
Four patients in the OT group and three in the pla-
cebo group were receiving psychotropic medications.
Results
Patients in the OT group displayed significantly increased
trust in others (P = 0.02), fewer tendencies towards sad-
ness (P = 0.02) and less disruptive behaviour (P = 0.03) in
the two days following intranasal drug administration.
They also showed a tendency towards fewer conflicts
with peers (P = 0.07) on the half-day following intranasal
administration. Table 2 shows these results in detail. Of
note, there was no difference between the two groups
before intranasal administration for any item.
In the group of the 19 patients with deletions (9 in the
OT group, 10 in the placebo group), a significant effect
of intranasal OT on disruptive behaviour was also found
(P = 0.04), as well as a trend towards more trust in others
(P = 0.05) fewer sadness tendencies (P = 0.07) and more
interest in friendship (P = 0.05) (data not shown). The
low number of patients with no deletion (n = 5) did not
allow statistical analysis (data not shown).
The same analysis was performed excluding the seven
patients who received psychotropic medications (4
patients in the OT group and 3 in the placebo group)
and showed that the OT group had less disruptive beha-
viour (P = 0.04) in the two days following intranasal drug
administration (data not shown).
The pre-post difference, which was calculated as “post-
administration late effect score” minus “pre-administration
score”, was significant in the OT group for the disruptive
behaviour (P = 0.01) and self-mutilation (P = 0.047) items,
whereas there was no difference in the placebo group
(Table 3). There was a trend (P = 0.07) towards a different
evolution in the pre-post difference between the two
groups for the disruptive behaviour item.
No statistical difference was observed in the scores
assessing eating behaviour between the two groups.
Nevertheless, five patients in the OT group (45%) and
one in the placebo group (10%) said that they did not
feel hungry and slightly decreased their food intake over
the two days following the intranasal administration.
The tests evaluating social skills showed a tendency
towards improvement in the OT group (n = 12). Eighty-
three percent of the patients in this group successfully
completed the Sally and Ann test compared with 50% in
the placebo group (n = 12) (P = 0.19, Figure 1). The
same tendency was observed with the Cartoons, with a
higher score obtained in the OT group than in the pla-
cebo group: 3.75 (1-18) vs. 6 (0-12) (P = 0.56). There
was no significant difference in the total RMET score
between the two groups: 7 (4-9) in the OT group vs. 5.5
(1-11) (P = 0.18).
Tolerance of OT was excellent with no effect on elec-
trocardiogram and PSA. No adverse event was observed
during the study.
Discussion
We were able to show for the first time that patients with
PWS who received a single intranasal administration of
Table 1 Criteria used by the staff to fill out the behavioural grid
Behavioural items Scoring criteria
Isolation
tendencies
playing solitary games, taking walks alone
Sadness tendencies mood state expressed by tears, complaints, frustration, irritation with others
Depressive
tendencies
remaining in bed, neglecting self-care, showing little motivation or interest, withdrawn
Self-depreciation belittling self, pointing out own incapacities and failings, expressing low self-value
Self-mutilation mutilations: scratching or scraping off skin, pulling out hair or eyebrows
Conflicts with
others
opposing others, verbal or physical disputes, other-directed complaints, making threats
Disruptive
behaviour
temper tantrums, sulking, running away, slamming doors, isolating self in room, breaking things, etc., in response to a conflict
or a frustration
Interest in
friendship
making friends with other patients, taking part in group activities
Interest in love
affairs
showing interest in having a special relationship with someone of the opposite sex (or not...)
Trust in others participating in group activities, talking with others while taking walks, spontaneously greeting others, introducing self to
caregivers or asking for help, etc.
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OT showed significantly higher trust in others, fewer sad-
ness tendencies and less disruptive behaviour, which may
in turn improve socialization. Patients also showed a ten-
dency towards less conflict with others on the half-day
following OT administration. Only late effects were
significantly different between the two groups. Moreover,
the changes in the disruptive behaviour and self-
mutilation scores were significant, whereas no change
was observed in the placebo group. Comparisons of the
two groups revealed no significant differences in the
changes but some trends could be observed (the disrup-
tive behaviour and depression items). The lack of
Table 2 Behavioural scores pre-and post-administration of OT in the placebo and OT groups; pre-administration score is
the mean of the scores reported on the two days before administration; Early effect is the immediate score recorded the
half-day following administration and late effect is the mean of the scores reported on the two days following
administration (the immediate score recorded the half-day following administration was excluded)
Variable Placebo Group OT Group P-value
Isolation tendencies
Pre-administration -0.111 ± 0.296 -0.083 ± 0.289 0.580
Early effect -0.250 ± 0.452 -0.083 ± 0.289 0.284
Late effect -0.111 ± 0.217 0 ± 0 0.070
Sadness tendencies
Pre-administration -0.208 ± 0.276 -0.194 ± 0.407 0.513
Early effect -0.083 ± 0.289 -0.083 ± 0.289 >0.99
Late effect -0.347 ± 0.379 -0.083 ± 0.289 0.021
Depressive tendencies
Pre-administration -0.028 ± 0.096 -0.056 ± 0.192 0.952
Early effect 0 ± 0 0 ± 0 >0.99
Late effect -0.125 ± 0.311 0 ± 0 0.149
Self-depreciation
Pre-administration -0.028 ± 0.096 -0.056 ± 0.192 0.952
Early effect 0 ± 0 -0.083 ± 0.289 0.317
Late effect -0.083 ± 0.289 0 ± 0 0.317
Self-mutilation
Pre-administration -0.069 ± 0.166 -0.278 ± 0.468 0.271
Early effect -0.083 ± 0.289 -0.083 ± 0.289 >0.99
Late effect -0.028 ± 0.096 -0.083 ± 0.195 0.482
Conflicts with others
Pre-administration -0.208 ± 0.276 -0.319 ± 0.359 0.467
Early effect -0.250 ± 0.452 0 ± 0 0.07
Late effect -0.125 ± 0.237 -0.111 ± 0.205 0.939
Disruptive behaviour
Pre-administration -0.361 ± 0.354 -0.431 ± 0.344 0.744
Early effect -0.250 ± 0.452 -0.167 ± 0.389 0.623
Late effect -0.306 ± 0.382 -0.042 ± 0.144 0.031
Interest in friendship
Pre-administration 0.806 ± 0.324 0.875 ± 0.433 0.349
Early effect 0.833 ± 0.389 0.917 ± 0.515 0.683
Late effect 0.778 ± 0.410 1.028 ± 0.234 0.088
Interest in love affairs
Pre-administration 0.847 ± 0.579 0.972 ± 0.531 0.589
Early effect 0.833 ± 0.389 0.917 ± 0.515 0.683
Late effect 0.847 ± 0.441 0.903 ± 0.411 0.714
Trust in others
Pre-administration 0.833 ± 0.389 0.861 ± 0.332 0.929
Early effect 0.917 ± 0.289 0.833 ± 0.389 0.546
Late effect 0.764 ± 0.366 1.028 ± 0.096 0.023
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significant difference may have been due to the well-
known high inter-individual variability of patients with
PWS or the low number of patients.
The lack of statistically significant difference in the
behaviour scores on the half-day following OT adminis-
tration suggests that early effects were not major in
these patients, while late effects (over the 2 days follow-
ing administration) were significant and relevant to both
the known actions of OT and the social dysfunctions
observed in these patients.
The genetic subtypes of PWS had been shown to partly
explain the well-known wide variability in the clinical fea-
tures. We recently showed that patients with deletions had
specific and significant relative weaknesses in the compre-
hension and picture completion subtests and relative
strength in object assembly compared with patients with-
out deletion [17]. This may also explain the results of the
tests we used, as 19 out of the 24 patients had deletions.
Interestingly, the effect of intranasal OT on disruptive
behaviour remained significant in the group of the 19
patients with deletions. The low number of patients (n =
5) without deletion did not allow statistical analysis and
further studies are needed with larger series.
The lack of statistically significant difference in the
various tests measuring social skills may have been due
to the fact that they were performed too early.
We are aware of the weaknesses in the protocol for
this pilot trial. For example, we used only one dose
without conducting a preliminary dose-finding study.
We did not use validated questionnaires for evaluating
behaviour because most of the validated questionnaires
are difficult to use for individuals with PWS. We thus
chose to use our in-house grid. We did not measure
plasmatic OT levels mainly because of the known diffi-
culties of sampling in these patients. We recently pub-
lished a report on the brain imaging abnormalities in
patients with PWS, particularly relatively hypoperfused
brain areas [21], and it would be interesting to take
these findings into account in future OT studies.
In conclusion, this preliminary study suggests that OT
may increase trust in others and decrease sadness tenden-
cies and disruptive behaviour in patients with PWS. It is
therefore tempting to suggest that OT may be used as a
therapeutic option in PWS. In any case, OT, like other
hormones, may become a substitutive treatment in PWS.
Further dose-effect and long-term studies are needed in
larger series combined with functional brain imaging
studies.
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